Modification of anti-tumor immunity by tolerogenic dendritic cells

Area of Science:

• Immunology
• Cancer Research
• Endocrinology

Background:

• Glucocorticoids (GC) exhibit immunosuppressive functions, partly through modulating dendritic cells (DCs).
• Dendritic cells play a crucial role in initiating and regulating immune responses, including anti-tumor immunity.

Purpose of the Study:

• To investigate the impact of tolerogenic GC-treated DCs on NK and T cell anti-tumor responses.
• To compare the effects of GC-treated DCs with immunogenic, CpG-activated DCs in a mouse model.

Main Methods:

• Utilized OT-1/Rag-/- mice with transgenic TCR in CD8+ T cells.
• Employed the EG7 tumor model expressing a specific peptide epitope.
• Analyzed NK and T cell responses, including cell populations, activation markers, and cytokine production.

Main Results:

• Immunogenic DCs (CpG and peptide-treated) protected against tumor growth by activating NK cells and cytotoxic CD8+ OT-1 T cells (producing IFNγ).
• Tolerogenic DCs (peptide and GC-treated) increased immature NK cells and induced suppressive CD8+ OT-1 T cells (Foxp3+, IL-10 secreting).

Conclusions:

• Tolerogenic DC generation is an immunosuppressive mechanism induced by GC.
• Tolerogenic DCs impair anti-tumor immunity by suppressing NK cell activity and promoting IL-10 secreting CD8+ regulatory T cells (Tregs).